Barclays’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $1.27M | Buy |
510,623
+476,503
| +1,397% | +$1.25M | ﹤0.01% | 2879 |
|
|
2026
Q2 | $91.8K | Buy |
34,120
+34,119
| +3,411,900% | +$88K | ﹤0.01% | 4075 |
|
|
2026
Q1 | $2 | Hold |
1
| – | – | ﹤0.01% | 4995 |
|
|
2025
Q4 | $2 | Sell |
1
-70
| -99% | -$108 | ﹤0.01% | 5182 |
|
|
2025
Q3 | $92 | Hold |
71
| – | – | ﹤0.01% | 5282 |
|
|
2025
Q2 | $23 | Sell |
71
-63,847
| -100% | -$19.2K | ﹤0.01% | 5142 |
|
|
2025
Q1 | $19.9K | Sell |
63,918
-29,389
| -31% | -$18.1K | ﹤0.01% | 4790 |
|
|
2024
Q4 | $87.1K | Buy |
93,307
+9,132
| +11% | +$10.2K | ﹤0.01% | 4627 |
|
|
2024
Q3 | $99.3K | Buy |
84,175
+63,702
| +311% | +$66.6K | ﹤0.01% | 4576 |
|
|
2024
Q2 | $15.7K | Sell |
20,473
-21,663
| -51% | -$60.3K | ﹤0.01% | 4475 |
|
|
2024
Q1 | $129K | Sell |
42,136
-39,924
| -49% | -$134K | ﹤0.01% | 4339 |
|
|
2023
Q4 | $264K | Buy |
82,060
+71,280
| +661% | +$244K | ﹤0.01% | 4287 |
|
|
2023
Q3 | $41.4K | Sell |
10,780
-1,175
| -10% | -$4.22K | ﹤0.01% | 3948 |
|
|
2023
Q2 | $39.2K | Buy |
+11,955
| New | +$40.6K | ﹤0.01% | 3932 |
|
|
2021
Q4 | – | Sell |
-8,218
| Closed | -$28K | – | 4568 |
|
|
2021
Q3 | $28K | Sell |
8,218
-27,009
| -77% | -$98.5K | ﹤0.01% | 4289 |
|
|
2021
Q2 | $137K | Sell |
35,227
-4,850
| -12% | -$19.1K | ﹤0.01% | 3716 |
|
|
2021
Q1 | $161K | Buy |
40,077
+24,718
| +161% | +$82.1K | ﹤0.01% | 3807 |
|
|
2020
Q4 | $35K | Sell |
15,359
-10,276
| -40% | -$47.9K | ﹤0.01% | 4546 |
|
|
2020
Q3 | $147K | Buy |
25,635
+2,061
| +9% | +$13.8K | ﹤0.01% | 4037 |
|
|
2020
Q2 | $173K | Buy |
+23,574
| New | +$110K | ﹤0.01% | 4170 |
|
|
2019
Q3 | – | Sell |
-267
| Closed | – | – | 7013 |
|
|
2019
Q2 | $0 | Sell |
267
-3,456
| -93% | -$6.17K | ﹤0.01% | 7161 |
|
|
2019
Q1 | $7K | Buy |
+3,723
| New | +$9.31K | ﹤0.01% | 6646 |
|
|
2018
Q4 | – | Sell |
-4,938
| Closed | -$28K | – | 7224 |
|
|
2018
Q3 | $28K | Buy |
4,938
+3,518
| +248% | +$26.7K | ﹤0.01% | 6343 |
|
|
2018
Q2 | $11K | Sell |
1,420
-1,118
| -44% | -$9.6K | ﹤0.01% | 6507 |
|
|
2018
Q1 | $18K | Buy |
2,538
+1,737
| +217% | +$14.1K | ﹤0.01% | 6469 |
|
|
2017
Q4 | $8K | Buy |
801
+683
| +579% | +$6.27K | ﹤0.01% | 6570 |
|
|
2017
Q3 | $1K | Buy |
118
+114
| +2,850% | +$949 | ﹤0.01% | 6761 |
|
|
2017
Q2 | $0 | Buy |
+4
| New | +$52 | ﹤0.01% | 6849 |
|
Other funds holding OVID
Barclays's OVID Position: Q3 2026 in Review
Barclays increased its Ovid Therapeutics (OVID) stake by 1,397% in Q3 2026, buying an estimated $1.25M and bringing the position to 510,623 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2879.
Barclays first reported a position in OVID in Q2 2017 and has held it in 28 quarters since. 33 funds tracked by Wall St. Rank hold OVID as of Q3 2026.
- Barclays held 510,623 shares of Ovid Therapeutics worth $1.27M as of Q3 2026.
- Barclays bought 476,503 Ovid Therapeutics shares in Q3 2026, an estimated $1.25M.
- Ovid Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2879 holding.
- Barclays first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 28 quarters since.
- 33 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.